Literature DB >> 7479776

Nonsense mutation in the phosphofructokinase muscle subunit gene associated with retention of intron 10 in one of the isolated transcripts in Ashkenazi Jewish patients with Tarui disease.

O Vasconcelos1, K Sivakumar, M C Dalakas, M Quezado, J Nagle, M Leon-Monzon, M Dubnick, D C Gajdusek, L G Goldfarb.   

Abstract

Mutations in the human phosphofructokinase muscle subunit gene (PFKM) are known to cause myopathy classified as glycogenosis type VII (Tarui disease). Previously described molecular defects include base substitutions altering encoded amino acids or resulting in abnormal splicing. We report a mutation resulting in phosphofructokinase deficiency in three patients from an Ashkenazi Jewish family. Using a reverse transcription PCR assay, PFKM subunit transcripts differing by length were detected in skeletal muscle tissue of all three affected subjects. In the longer transcript, an insertion of 252 nucleotides totally homologous to the structure of the 10th intron of the PFKM gene was found separating exon 10 from exon 11. In addition, two single base transitions were identified by direct sequencing: [exon 6; codon 95; CGA (Arg) to TGA (stop)] and [exon 7; codon 172; ACC (Thr) to ACT (Thr)] in either transcript. Single-stranded conformational polymorphism and restriction enzyme analyses confirmed the presence of these point substitutions in genomic DNA and strongly suggested homozygosity for the pathogenic allele. The nonsense mutation at codon 95 appeared solely responsible for the phenotype in these patients, further expanding genetic heterogeneity of Tarui disease. Transcripts with and without intron 10 arising from identical mutant alleles probably resulted from differential pre-mRNA processing and may represent a novel message from the PFKM gene.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7479776      PMCID: PMC40788          DOI: 10.1073/pnas.92.22.10322

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  26 in total

1.  PHOSPHOFRUCTOKINASE DEFICIENCY IN SKELETAL MUSCLE. A NEW TYPE OF GLYCOGENOSIS.

Authors:  S TARUI; G OKUNO; Y IKURA; T TANAKA; M SUDA; M NISHIKAWA
Journal:  Biochem Biophys Res Commun       Date:  1965-05-03       Impact factor: 3.575

2.  Rapid and sensitive detection of point mutations and DNA polymorphisms using the polymerase chain reaction.

Authors:  M Orita; Y Suzuki; T Sekiya; K Hayashi
Journal:  Genomics       Date:  1989-11       Impact factor: 5.736

3.  Regional assignment of human liver-type 6-phosphofructokinase to chromosome 21q22.3 by using somatic cell hybrids and a monoclonal anti-L antibody.

Authors:  M Van Keuren; H Drabkin; I Hart; D Harker; D Patterson; S Vora
Journal:  Hum Genet       Date:  1986-09       Impact factor: 4.132

4.  Genetic defect in muscle phosphofructokinase deficiency. Abnormal splicing of the muscle phosphofructokinase gene due to a point mutation at the 5'-splice site.

Authors:  H Nakajima; N Kono; T Yamasaki; K Hotta; M Kawachi; M Kuwajima; T Noguchi; T Tanaka; S Tarui
Journal:  J Biol Chem       Date:  1990-06-05       Impact factor: 5.157

5.  Common mutations in the phosphofructokinase-M gene in Ashkenazi Jewish patients with glycogenesis VII--and their population frequency.

Authors:  J B Sherman; N Raben; C Nicastri; Z Argov; H Nakajima; E M Adams; C M Eng; T M Cowan; P H Plotz
Journal:  Am J Hum Genet       Date:  1994-08       Impact factor: 11.025

6.  Alternative splicing: a mechanism for phenotypic rescue of a common inherited defect.

Authors:  H Morisaki; T Morisaki; L K Newby; E W Holmes
Journal:  J Clin Invest       Date:  1993-05       Impact factor: 14.808

Review 7.  Mutations in muscle phosphofructokinase gene.

Authors:  N Raben; J B Sherman
Journal:  Hum Mutat       Date:  1995       Impact factor: 4.878

8.  Signals for the selection of a splice site in pre-mRNA. Computer analysis of splice junction sequences and like sequences.

Authors:  Y Ohshima; Y Gotoh
Journal:  J Mol Biol       Date:  1987-05-20       Impact factor: 5.469

9.  Human and rat chromosomal localization of two genes for 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase by analysis of somatic cell hybrids and in situ hybridization.

Authors:  C E Hilliker; M I Darville; M S Aly; M Chikri; C Szpirer; P Marynen; G G Rousseau; J J Cassiman
Journal:  Genomics       Date:  1991-08       Impact factor: 5.736

10.  Functional expression of human mutant phosphofructokinase in yeast: genetic defects in French Canadian and Swiss patients with phosphofructokinase deficiency.

Authors:  N Raben; R Exelbert; R Spiegel; J B Sherman; H Nakajima; P Plotz; J Heinisch
Journal:  Am J Hum Genet       Date:  1995-01       Impact factor: 11.025

View more
  4 in total

1.  Glycogenosis type VII (Tarui disease) in a Swedish family: two novel mutations in muscle phosphofructokinase gene (PFK-M) resulting in intron retentions.

Authors:  R C Nichols; O Rudolphi; B Ek; R Exelbert; P H Plotz; N Raben
Journal:  Am J Hum Genet       Date:  1996-07       Impact factor: 11.025

2.  PFKM inhibits doxorubicin-induced cardiotoxicity by enhancing oxidative phosphorylation and glycolysis.

Authors:  Min Zhou; Xiao Sun; Chunli Wang; Fengdan Wang; Chuibi Fang; Zhenlei Hu
Journal:  Sci Rep       Date:  2022-07-08       Impact factor: 4.996

Review 3.  The sarcomeric M-region: a molecular command center for diverse cellular processes.

Authors:  Li-Yen R Hu; Maegen A Ackermann; Aikaterini Kontrogianni-Konstantopoulos
Journal:  Biomed Res Int       Date:  2015-04-15       Impact factor: 3.411

4.  A genome-wide association study of early-onset breast cancer identifies PFKM as a novel breast cancer gene and supports a common genetic spectrum for breast cancer at any age.

Authors:  Habibul Ahsan; Jerry Halpern; Muhammad G Kibriya; Brandon L Pierce; Lin Tong; Eric Gamazon; Valerie McGuire; Anna Felberg; Jianxin Shi; Farzana Jasmine; Shantanu Roy; Rachelle Brutus; Maria Argos; Stephanie Melkonian; Jenny Chang-Claude; Irene Andrulis; John L Hopper; Esther M John; Kathi Malone; Giske Ursin; Marilie D Gammon; Duncan C Thomas; Daniela Seminara; Graham Casey; Julia A Knight; Melissa C Southey; Graham G Giles; Regina M Santella; Eunjung Lee; David Conti; David Duggan; Steve Gallinger; Robert Haile; Mark Jenkins; Noralane M Lindor; Polly Newcomb; Kyriaki Michailidou; Carmel Apicella; Daniel J Park; Julian Peto; Olivia Fletcher; Isabel dos Santos Silva; Mark Lathrop; David J Hunter; Stephen J Chanock; Alfons Meindl; Rita K Schmutzler; Bertram Müller-Myhsok; Magdalena Lochmann; Lars Beckmann; Rebecca Hein; Enes Makalic; Daniel F Schmidt; Quang Minh Bui; Jennifer Stone; Dieter Flesch-Janys; Norbert Dahmen; Heli Nevanlinna; Kristiina Aittomäki; Carl Blomqvist; Per Hall; Kamila Czene; Astrid Irwanto; Jianjun Liu; Nazneen Rahman; Clare Turnbull; Alison M Dunning; Paul Pharoah; Quinten Waisfisz; Hanne Meijers-Heijboer; Andre G Uitterlinden; Fernando Rivadeneira; Dan Nicolae; Douglas F Easton; Nancy J Cox; Alice S Whittemore
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2014-02-03       Impact factor: 4.254

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.